Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Abivax SA American Depositary Shares (ABVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ABVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -1.89% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 649.94M USD | Price to earnings Ratio - | 1Y Target Price 35.85 |
Price to earnings Ratio - | 1Y Target Price 35.85 | ||
Volume (30-day avg) 263212 | Beta 1.42 | 52 Weeks Range 5.50 - 16.63 | Updated Date 03/29/2025 |
52 Weeks Range 5.50 - 16.63 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.66 |
Earnings Date
Report Date 2025-03-31 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1178.84% |
Management Effectiveness
Return on Assets (TTM) -46.69% | Return on Equity (TTM) -171.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 321830860 | Price to Sales(TTM) 35.55 |
Enterprise Value 321830860 | Price to Sales(TTM) 35.55 | ||
Enterprise Value to Revenue 157.63 | Enterprise Value to EBITDA -12.66 | Shares Outstanding 62917700 | Shares Floating 25189319 |
Shares Outstanding 62917700 | Shares Floating 25189319 | ||
Percent Insiders - | Percent Institutions 44.66 |
Analyst Ratings
Rating 4.43 | Target Price 35.85 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Abivax SA American Depositary Shares
Company Overview
History and Background
Abivax SA is a biotechnology company focused on developing novel therapies for chronic inflammatory diseases, viral infections, and cancer. Founded in 2013, the company has made significant strides in advancing its lead drug candidate, obefazimod, through clinical trials.
Core Business Areas
- Inflammatory Diseases: Development of therapies targeting inflammatory bowel disease (IBD), particularly ulcerative colitis.
- Viral Infections: Research and development focused on treating chronic hepatitis B (HBV) and HIV.
Leadership and Structure
The leadership team includes experienced executives in the biotechnology and pharmaceutical industries. The organizational structure is typical of a biotech company, with dedicated teams for research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Obefazimod (ABX464): A first-in-class oral therapeutic candidate for ulcerative colitis and other inflammatory diseases. It is in Phase 3 clinical trials. Market share is currently 0% as the drug is not yet approved. Competitors include marketed drugs from companies like Johnson & Johnson (JNJ), AbbVie (ABBV), and Takeda (TAK).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investments in research and development. The market for inflammatory disease treatments is substantial and growing.
Positioning
Abivax positions itself as an innovator in developing novel therapies for inflammatory diseases and viral infections. Its competitive advantage lies in its proprietary drug candidates and its focus on addressing unmet medical needs.
Total Addressable Market (TAM)
The TAM for ulcerative colitis and inflammatory bowel diseases is estimated to be in the tens of billions of dollars. Abivax aims to capture a portion of this market with Obefazimod, targeting patients who have failed existing therapies.
Upturn SWOT Analysis
Strengths
- Innovative drug candidate (Obefazimod)
- Strong intellectual property portfolio
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on a single lead drug candidate
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- No approved products currently generating revenue
Opportunities
- Successful completion of clinical trials and regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new indications for Obefazimod
- Advancements in understanding of inflammatory diseases
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- TAK
- BMY
- MRK
Competitive Landscape
Abivax faces strong competition from established pharmaceutical companies with approved therapies for inflammatory diseases. Its competitive advantage lies in the potential for Obefazimod to offer a novel mechanism of action and improved efficacy.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily reflected in advancing clinical trials and securing funding.
Future Projections: Future growth is contingent on the successful development and commercialization of Obefazimod and other pipeline candidates. Analyst estimates vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing Phase 3 clinical trials for Obefazimod in ulcerative colitis and exploring new indications for the drug.
Summary
Abivax is a clinical-stage biotech company with a promising lead drug candidate, Obefazimod. Its success hinges on the outcome of ongoing clinical trials and regulatory approval. It faces competition from established pharmaceutical giants and needs to manage its cash burn effectively. Successful clinical trials are vital for future growth and potential partnerships.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abivax SA American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-10-20 | CEO & Director Mr. Marc M. P. de Garidel M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.abivax.com |
Full time employees 69 | Website https://www.abivax.com | ||
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.